Peer Review History

Original SubmissionOctober 28, 2024
Decision Letter - Alessandro De Cassai, Editor

PONE-D-24-44917Effect of opioid-free anesthesia combined with pectoral nerve block on the quality of recovery in patients after mastectomy: A randomized, controlled trialPLOS ONE

Dear Dr. Luo,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Feb 03 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Alessandro De Cassai, MD

Academic Editor

PLOS ONE

Journal Requirements:

 When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf. 2. We are unable to open your Supporting Information file [renamed_7e522.sav]. Please kindly revise as necessary and re-upload. 3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The paper was well written with respect to the statistical presentation.

The study was appropriately designed with power considerations requiring a sample size of 63 patients per group was and expanded to 136 patients to compensate for any dropouts. Both parametric and non parametric analysis approaches were performed as needed. Efficacy and adverse events were compared as per the two arms. The tables were well formatted and easily interpretable. Both groups were fairly well balanced. The analysis was simple with univariate comparisons.

As per the authors the groups were similar with respect to outcomes. That is, while OFA contributes to a reduction in adverse events, its integration with PECS blocks does not improve QoR or postoperative analgesia at 24 h post-mastectomy. Moreover, OFA was associated with a prolonged extubation time.

Reviewer #2: Dear Authors, thank you for the opportunity to review your study.

You have selected an interesting and contemporary topic that still needs a lot of detailed studies. I’ve also really appreciated the idea to incorporate regional anaesthesia, another current subject. However the manuscript presents important inaccuracies and requires some major revisions.

Firstly, the main outcome of the paper is not so innovative since ERAS protocols already promotes opioid alternatives to provide opioid reduced anesthesia (ORA) and OFA to patients.

Secondly, the reason why your main outcome refers to a study that doesn’t include mammary surgery is not clear (Bu eat al. “Validation of the Chinese version of the Quality of Recovery-15 Score and Its Comparison with the Post-Operative Quality Recovery Scale.”). Furthermore, in my opinion, the value of QoR-15 you used as baseline (106,5) is very low and does not represent the real quality of recovery of patients undergoing mastectomy beyond the use of opioids. This is also clear from your results: the lowest value of QoR-15 you have registered is 127.

In the end, I think it would’ve been interesting to analyse the variation between the QoR-15 before the surgery and after to evaluate if there were any differences between the two groups.

Obviously, changing the main outcome would change the sample size, can you clarify the choice you made?

In addition some minor revision that requires your attention:

- At page 5, lines 19-20; you should specify the type of surgery maybe writing “undergoing total or partial mastectomy, with axillary lymph node dissection or sentinel lymph node biopsy”;

- At page 6, lines 20-21; even if implicit, you should explain better the type of block you performed and the dosage and type of anaesthetic you used for each injection;

- At page 7, talking about muscle relaxation, include the neuromuscular monitoring;

- At page 8, clarify what you did include in “adverse events”;

- In table n.1 you should also consider the QoR-15 pre-surgery;

- Consider a rearrangement of the Discussion paragraph as it’s too long compared to the overall length of the article.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: Yes:  Marco Covotta

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Revision 1

PLOS ONE Editorial Office

PLOS ONE

Dear Dr. De Cassai and the PLOS ONE Editorial Team,

Thank you for the opportunity to revise our manuscript titled "Effect of opioid-free anesthesia combined with pectoral nerve block on the quality of recovery in patients after mastectomy: A randomized, controlled trial" (Manuscript ID: PONE-D-24-44917). We appreciate the constructive feedback provided by you and the reviewers, which has helped us improve the quality of our work.

Below, we address each of the reviewers' comments and outline the changes made to the manuscript:

Reviewer #1 Comments:

We appreciate the reviewer's positive feedback regarding the statistical presentation and study design. We have ensured that all statistical analyses are clearly described in the revised manuscript.

Reviewer #2 Comments:

1.“Firstly, the main outcome of the paper is not so innovative since ERAS protocols already promotes opioid alternatives to provide opioid reduced anesthesia (ORA) and OFA to patients.”

- We acknowledge the concern regarding the innovation of our study. While ERAS protocols do promote opioid alternatives, our research specifically investigates the effects of opioid-free anesthesia (OFA) combined with regional blocks on the quality of recovery (QoR) after mastectomy. This focus on OFA in breast surgery is novel and provides specific data on its impact on postoperative recovery, pain management, and adverse events. Importantly, our study has already implemented several core measures of ERAS, including multimodal analgesia, PONV prevention, and total intravenous anesthesia (TIVA), which is recommanded by ERAS sociaty[1]. These elements not only enhance the QoR but also increase the relevance of our study as a reference for the implementation of ERAS protocols in clinical practice.

2.“Secondly, the reason why your main outcome refers to a study that doesn’t include mammary surgery is not clear (Bu eat al. “Validation of the Chinese version of the Quality of Recovery-15 Score and Its Comparison with the Post-Operative Quality Recovery Scale.”). Furthermore, in my opinion, the value of QoR-15 you used as baseline (106,5) is very low and does not represent the real quality of recovery of patients undergoing mastectomy beyond the use of opioids. This is also clear from your results: the lowest value of QoR-15 you have registered is 127.”

- We selected Bu et al.'s study[2] as a reference because it validated the Chinese version of the QoR-15 and was relevant to our patient population in mainland China. We clarify that Bu's study does include breast surgery, categorizing it under “General” surgery type in Table 1 in their study. Our findings of a higher postoperative QoR-15 score (127.4±14.0) compared to Bu's baseline score (106.5) reflect advancements in perioperative management, particularly in minimizing opioid use. We have recalculated the required sample size based on the QoR-15 scores from Zhang et al.'s study[3], which reported a postoperative 24-hour QoR-15 score of 132.0 ± 12.0 for patients receiving opioid-based anesthesia (OBA). Our sample size has been recalculated based on this new reference, ensuring that our study is adequately powered to detect clinically meaningful differences.

Sample Size Calculation:

Using the formula for comparing two means in clinical trials:

 and 

, .

with a MICD of 8, SD of 12, and a significance level of 0.05. Therefore, we propose a total sample size of 74 patients (37 per group) to detect a clinically meaningful difference in QoR-15 scores. This revised calculation ensures that our study is adequately powered to assess the impact of OFA combined with regional blocks on the quality of recovery in patients undergoing mastectomy.

3.“In the end, I think it would’ve been interesting to analyse the variation between the QoR-15 before the surgery and after to evaluate if there were any differences between the two groups.”

- We have added an analysis of the variation in QoR-15 scores before and after surgery in Table 3. The results show no statistically significant difference between the two groups, with changes of -13.4±10.1 in the OFA group versus -12.2±12.2 in the OBA group (MD=-1.2, P=0.54).

4.**Minor Revisions**:

We have made the following revisions as per your suggestions:

‘At page 5, lines 19-20; you should specify the type of surgery maybe writing “undergoing total or partial mastectomy, with axillary lymph node dissection or sentinel lymph node biopsy”;’

- Specified the types of surgeries performed (total or partial mastectomy, with axillary lymph node dissection or sentinel lymph node biopsy) on Page 5, Line 19-20.

“At page 6, lines 20-21; even if implicit, you should explain better the type of block you performed and the dosage and type of anaesthetic you used for each injection;”

- Provided a detailed explanation of the PECS block technique, including the dosage and type of anesthetic used, on Page 6, Line 20-22.

“At page 7, talking about muscle relaxation, include the neuromuscular monitoring;”

- Included a statement regarding the lack of neuromuscular monitoring on Page 7, Line 16-18.

‘At page 8, clarify what you did include in “adverse events”;’

- Clarified the definition of "adverse events" on Page 9, Line 1-2.

“In table n.1 you should also consider the QoR-15 pre-surgery;”

- Updated Table 1 to include pre-surgery QoR-15 scores.

“Consider a rearrangement of the Discussion paragraph as it’s too long compared to the overall length of the article.”

- Rearranged the Discussion section for improved clarity and conciseness on Page 18-20.

We believe these revisions adequately address the reviewers' concerns and enhance the quality of our manuscript. We appreciate the opportunity to improve our work and look forward to your feedback on our revised submission.

Thank you for your consideration.

Sincerely,

Qingyan Luo

From the Department of Anesthesiology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.

Reference

1. Temple-Oberle C, Shea-Budgell M, Tan M, Semple J, Schrag C, Barreto M, et al. Consensus Review of Optimal Perioperative Care in Breast Reconstruction: Enhanced Recovery after Surgery (ERAS) Society Recommendations. Plastic and reconstructive surgery. 2017;139(5):1056e-71e.

2. Bu X, Zhang J, Zuo Y. Validation of the Chinese Version of the Quality of Recovery-15 Score and Its Comparison with the Post-Operative Quality Recovery Scale. The patient. 2016;9(3):251-9.

3. Qingfen Z, Yaqing W, Haiyan A, Yi F. Postoperative recovery after breast cancer surgery: A randomised controlled trial of opioid-based versus opioid-free anaesthesia with thoracic paravertebral block. Eur J Anaesthesiol. 2023;40(8).

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Alessandro De Cassai, Editor

Effect of opioid-free anesthesia combined with pectoral nerve block on the quality of recovery in patients after mastectomy: A randomized, controlled trial

PONE-D-24-44917R1

Dear Dr. Luo,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Alessandro De Cassai, MD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

According to Reviewers comments and my onw assessment your manuscript could be accepted

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: Thank you for requesting this further revision. the authors have made the requested revisions. for me, the manuscript can be accepted.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: Yes:  Covotta Marco, MD, IRCCS Regina Elena National Cancer Institute, Rome, Italy

**********

Formally Accepted
Acceptance Letter - Alessandro De Cassai, Editor

PONE-D-24-44917R1

PLOS ONE

Dear Dr. Luo,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Alessandro De Cassai

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .